Compounds > atomoxetine hydrochloride
Page last updated: 2024-08-23

atomoxetine hydrochloride and Neurally Mediated Faint

atomoxetine hydrochloride has been researched along with Neurally Mediated Faint in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Hamzeh, R; Parkash, R; Raj, SR; Sandhu, RK; Seifer, C; Sheldon, RS1
Hamzeh, R; Raj, SR; Sandhu, RK; Sheldon, RS1
Angihan, J; Ayala-Paredes, FA; Bennett, G; Guzman, JC; Kus, T; Lei, L; Maxey, C; Raj, SR; Safdar, S; Sheldon, RS1

Trials

3 trial(s) available for atomoxetine hydrochloride and Neurally Mediated Faint

ArticleYear
Atomoxetine for suppression of vasovagal syncope.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2023, Volume: 33, Issue:1

    Topics: Adult; Aged; Atomoxetine Hydrochloride; Female; Humans; Middle Aged; Retrospective Studies; Syncope; Syncope, Vasovagal; Tilt-Table Test

2023
The Seventh Prevention of Syncope Trial (POST VII)-A randomized clinical trial of atomoxetine for the prevention of vasovagal syncope: Rationale and study design.
    American heart journal, 2023, Volume: 262

    Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Double-Blind Method; Humans; Quality of Life; Recurrence; Syncope, Vasovagal

2023
A proof of principle study of atomoxetine for the prevention of vasovagal syncope: the Prevention of Syncope Trial VI.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2019, Nov-01, Volume: 21, Issue:11

    Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Male; Stroke Volume; Syncope, Vasovagal; Tilt-Table Test; Treatment Outcome

2019